RT Journal Article
SR Electronic
T1 Decoding Prodromal Parkinson’s Disease: Clinical Differences between Isolated Hyposmia and REM Sleep Behavior Disorder
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.03.18.24304459
DO 10.1101/2024.03.18.24304459
A1 Banerjee, Luke Vikram
A1 Pasquini, Jacopo
A1 Henderson, Robin
A1 Pavese, Nicola
A1 Anderson, Kirstie N
YR 2024
UL http://medrxiv.org/content/early/2024/03/18/2024.03.18.24304459.abstract
AB Background The prodromal phase of Parkinson’s disease (PD), much like the disease itself, displays marked heterogeneity, with varied rates of progression and symptom severities. A detailed clinical characterization of prodromal subgroups may provide useful insights for both clinical and research settings.Objectives To compare clinical assessments in patients with idiopathic rapid eye movement sleep behavior disorder (iRBD) and those with isolated hyposmia.Methods A cross-sectional study was conducted on 191 patients with iRBD, 213 patients with isolated hyposmia and 150 healthy controls recruited in the Parkinson’s Progression Markers Initiative. The earliest available assessment for each participant was selected. Our analysis investigated and compared the Montreal Cognitive Assessment, Scales for Outcomes in Parkinson’s Disease Autonomic Dysfunction (SCOPA-AUT) and Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Parts I, II and III scores across the three groups. To assess differences, after adjusting for age and sex, we employed permutations testing. We further investigated the specific question items that contributed most significantly to the observed variations between the groups.Results We found significant differences between the healthy control group and a combined prodromal group across all assessment categories, with prodromal participants displaying poorer scores. For between prodromal groups comparison, significant differences emerged in SCOPA-AUT and MDS-UPDRS Part I scores, with the iRBD group presenting with more severe scores.Conclusion Our study highlights that even in the premotor stage of PD, clinical distinctions exist in terms of autonomic burden between individuals with iRBD and those with isolated hyposmia.Competing Interest StatementRelating to current research covered in this study regardless of date: LVB, JP and RH report no financial disclosures or conflicts of interest in relation to the manuscript. NP and KNA receive grant funding from the Michael J Fox Foundation to run the Parkinson's Progression Markers Initiative study in Newcastle upon Tyne. All disclosures for preceding 12-months regardless of relation to this study: LVB, JP and RH report no sources of financial support and funding for the past year, including those unrelated to the manuscript. Author NP sits on advisory boards for Bial, Hoffmann-La Roche, Inc., and Abbvie, and receives grants from the Independent Research Fund Denmark, Danish Parkinson's disease Association, Parkinson's UK, GE Healthcare Grant, Multiple System Atrophy Trust and F. Hoffmann-La Roche, Inc. Author KA has attended advisory boards for Janssen Cilag, Idorsia and has received grant funding from Closing the Gap mental health network, and has had speakers fees from Bioprojet, Flynn Pharma and Idorsia.Funding StatementFunding Sources: LVB's research placement was funded by the Specialised Foundation Programme, Northern Foundation School, NHS England. This funding enabled his focused research activities. PPMI - a public-private partnership - is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including 4D Pharma, Abbvie, AcureX, Allergan, Amathus Therapeutics, Aligning Science Across Parkinson's, AskBio, Avid Radiopharmaceuticals, BIAL, Biogen, Biohaven, BioLegend, BlueRock Therapeutics, Bristol-Myers Squibb, Calico Labs, Celgene, Cerevel Therapeutics, Coave Therapeutics, DaCapo Brainscience, Denali, Edmond J. Safra Foundation, Eli Lilly, Gain Therapeutics, GE HealthCare, Genentech, GSK, Golub Capital, Handl Therapeutics, Insitro, Janssen Neuroscience, Lundbeck, Merck, Meso Scale Discovery, Mission Therapeutics, Neurocrine Biosciences, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi, Servier, Sun Pharma Advanced Research Company, Takeda, Teva, UCB, Vanqua Bio, Verily, Voyager Therapeutics, the Weston Family Foundation and Yumanity Therapeutics.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:PPMI data was gathered in accordance with the Declaration of Helsinki after approval of the local ethics committees of the participating sites Data was acquired from the Parkinson's Progression Markers Initiative (PPMI) database, downloaded on December 21st, 2023. PPMI is a worldwide, multicenter, longitudinal cohort study which aims to identify biological markers of Parkinson's disease onset and progression. Data is available at https://www.ppmi-info.org/access-data-specimens/download-data (Research Resource Identifier:SCR_006431). For current study details visit www.ppmi- info.org. This study used tier 1 data, openly available from PPMI, and tier 3 data, obtained from PPMI upon request after approval by the PPMI Data Access Committee.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData was acquired from the Parkinson's Progression Markers Initiative (PPMI) database, downloaded on December 21st, 2023. PPMI is a worldwide, multicenter, longitudinal cohort study which aims to identify biological markers of Parkinson's disease onset and progression. Data is available at https://www.ppmi-info.org/access-data-specimens/download-data (Research Resource Identifier:SCR_006431). For current study details visit www.ppmi-info.org. This study used tier 1 data, openly available from PPMI, and tier 3 data, obtained from PPMI upon request after approval by the PPMI Data Access Committee.